UNICHEM LABORATORIES LTD. - 506690 - Board Meeting Intimation for To Inter-Alia Consider And Approve The Unaudited Financial Results For The Quarter Ended June 30, 2020
UNICHEM LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2020 ,inter alia, to consider and approve Unaudited Financial Results for the quarter ended June 30, 2020 UNICHEM LABORATORIES LTD. - 506690 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication for updation of shareholder details UNICHEM LABORATORIES LTD. - 506690 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication for updation of shareholder details
Unichem Laboratories gets USFDA nod for drug to treat irregular heartbeat
The company has received abbreviated new drug application (ANDA) approval for its Amiodarone tablets, USP, 200 mg from the United States Food and Drug Administration (USFDA), Unichem Labs said in a filing to the BSE. UNICHEM LABORATORIES LTD. - 506690 - Announcement Under Reuglation 30 (LODR) - ANDA Approval From USFDA For Unichem'S Amiodarone Tablets
Announcement under Reuglation 30 (LODR) - ANDA Approval from USFDA for Unichem's Amiodarone Tablets UNICHEM LABORATORIES LTD. - 506690 - Shareholding for the Period Ended June 30, 2020
Unichem Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2020. For more details, kindly Click here UNICHEM LABORATORIES LTD. - 506690 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance Certificate under regulation 74[5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2020. UNICHEM LABORATORIES LTD. - 506690 - Statement Of Investor Complaints For The Quarter Ended June 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- PRADEEP BHANDARIDesignation :- Company Secretary and Compliance Officer Unichem Labs gets USFDA nod for spasticity relief tablets
Drug firm Unichem Laboratories on Friday said it has received approval from the US health regulator to market its Baclofen tablets indicated for alle UNICHEM LABORATORIES LTD. - 506690 - ANDA Approval From USFDA For Unichem'S Baclofen Tablets
ANDA approval from United States Food and Drug Administration (USFDA) for Unichem's Baclofen Tablets.